CTIS2023-506737-30-00招募中1 期
A Phase 1/2, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Intravenous Doses of BMN 351 in Participants with Duchenne Muscular Dystrophy - 351-201
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 17（—）
- 性别
- Male
入选标准
- •1. Is male and age 4 through 10 years at Screening., 2. Clinical diagnosis of Duchenne muscular dystrophy in the opinion of the investigator resulting from a documented dystrophin mutation in the DMD gene amenable to exon 51 skipping as reviewed by a central genetic counselor., 3. Ambulatory at Screening, defined as able to walk independently without assistive devices and complete the timed 10 meter walk/run test in 8 seconds or less., 4. Not currently daytime ventilator dependent and not expected to need daytime mechanical or noninvasive ventilation within the next year in the opinion of the investigator., 5. Currently receiving treatment with oral corticosteroids, on a stable dose for at least 12 weeks prior to Baseline, and must remain on a consistent dose/dose regimen throughout the study except for modifications to accommodate changes in weight., 6. Normal urinalysis at Screening (trace protein allowed).
排除标准
- •1. For children 7 years of age or older, forced expiratory volume (FEV1) < 60% of predicted., 2. Current or history of liver or renal disease., 3. Left ventricular ejection fraction (LVEF) < 55% based on an echocardiogram (ECHO) performed within 3 months prior to the Baseline (Day 1) visit., 4. Mean QT interval corrected with Fridericia’s method (QTcF) = 450 msec on the Screening electrocardiogram (ECG) conducted in triplicate., 5. Platelet count of < 150 x 10^9/L at Screening., 6. Renal function laboratory parameters outside of prespecified values as defined per protocol., 7. Treatment with any exon skipping therapy within 12 weeks prior to Baseline (Day 1) or with any gene therapy for the treatment of DMD at any time.
研究者
相似试验
进行中（未招募）
1 期
A Phase 1/ 2 Study of the Oral Form of MLN9708 with Melphalan and Prednisone for Patients with Newly Diagnosed Multiple Myelomaewly diagnosed multiple myelomaMedDRA version: 16.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2010-023772-71-CZMillennium Pharmaceuticals, Inc158
进行中（未招募）
1 期
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of MLN9708, a Next-Generation Proteasome Inhibitor, Administered in Combination with a Standard Care Regimen of Melphalan and Prednisone in Patients With Newly-Diagnosed Multiple Myeloma Requiring Systemic Treatment.Estudio de fase 1/2, de aumento de dosis, abierto, de la formulación oral de MLN9708, un inhibidor de proteosoma de nueva generación, administrado en combinación con un régimen habitual de melfalán y prednisona en pacientes con mieloma múltiple de nuevo diagnóstico que precisan tratamiento sistémico -mieloma múltiple de nuevo diagnósticoMedDRA version: 12.1Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2010-023772-71-ESMillennium Pharmaceuticals, Inc163
进行中（未招募）
不适用
A Phase 1/ 2 Study of the Oral Form of MLN9708 with Melphalan and Prednisone for Patients with Newly Diagnosed Multiple Myelomaewly diagnosed multiple myelomaMedDRA version: 14.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-023772-71-ITMILLENNIUM PHARMACEUTICALS, INC.163
进行中（未招募）
1 期
A Phase 1/ 2 Study of the Oral Form of MLN9708 with Melphalan and Prednisone for Patients with Newly Diagnosed Multiple MyelomaEUCTR2010-023772-71-GBMillennium Pharmaceuticals, Inc61
尚未招募
2 期
A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects with NUT Midline Carcinoma (NMC) and Other Cancers (BET115521)NUT Midline Carcinoma and other solid tumors10027655NL-OMON43804GlaxoSmithKline10